deferoxamine has been researched along with Obesity in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this work, we analyzed deferoxamine effects on adipose tissue fibro-inflammation during obesity induced by diet in mice." | 8.31 | Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction. ( Caria, CREP; de Morais, TR; Ferreira, APT; Gambero, A; Gotardo, EMF; Ribeiro, ML, 2023) |
| "In this work, we analyzed deferoxamine effects on adipose tissue fibro-inflammation during obesity induced by diet in mice." | 4.31 | Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction. ( Caria, CREP; de Morais, TR; Ferreira, APT; Gambero, A; Gotardo, EMF; Ribeiro, ML, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Gotardo, EMF | 1 |
| de Morais, TR | 1 |
| Ferreira, APT | 1 |
| Caria, CREP | 1 |
| Ribeiro, ML | 1 |
| Gambero, A | 1 |
| Higashida, K | 1 |
| Takeuchi, N | 1 |
| Inoue, S | 1 |
| Hashimoto, T | 1 |
| Nakai, N | 1 |
| Tajima, S | 1 |
| Ikeda, Y | 1 |
| Sawada, K | 1 |
| Yamano, N | 1 |
| Horinouchi, Y | 1 |
| Kihira, Y | 1 |
| Ishizawa, K | 1 |
| Izawa-Ishizawa, Y | 1 |
| Kawazoe, K | 1 |
| Tomita, S | 1 |
| Minakuchi, K | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
1 review available for deferoxamine and Obesity
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
3 other studies available for deferoxamine and Obesity
| Article | Year |
|---|---|
Deferoxamine Interference in Fibro-inflammation: Additional Action in Control of Obese Adipose Tissue Dysfunction.
Topics: Adipose Tissue; Animals; Deferoxamine; Humans; Inflammation; Insulin Resistance; Liver; Mice; Mice, | 2023 |
Iron deficiency attenuates catecholamine‑stimulated lipolysis via downregulation of lipolysis‑related proteins and glucose utilization in 3T3‑L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Catecholamines; Deferoxamine; Down-Regulation; Glucose; Iron; Iro | 2020 |
Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
Topics: Adipose Tissue, White; Adiposity; Animals; Cell Size; Chelation Therapy; Cytochrome b Group; Cytokin | 2012 |